[Mycophenolate mofetil versus cyclosporine A in children with primary refractory nephrotic syndrome].

医学 微小变化病 局灶节段性肾小球硬化 霉酚酸酯 胃肠病学 肾病综合征 内科学 耐火材料(行星科学) 强的松 肾小球肾炎 霉酚酸 移植 儿科 物理 天体生物学
作者
Houfa Geng,Lu Ji,C Y Chen,Juan Tu,H R Li,Rebecca Bao,Yu‐Feng Lin
出处
期刊:PubMed 卷期号:56 (9): 651-656 被引量:3
标识
DOI:10.3760/cma.j.issn.0578-1310.2018.09.004
摘要

Objective: To compare the efficacy and safety of mycophenolate mofetil versus cyclosporine A in treating children with primary refractory nephrotic syndrome. Methods: Conducted a prospective randomized controlled clinical trial in 62 pediatric patients (including 44 boys and 18 girls), age ranged from 2.1 to 17.0 years; 32 cases presented with frequently relapsing nephrotic syndrome (FRNS) and 30 cases presented with steroid-resistant nephrotic syndrome (SRNS), who were admitted to department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics from October 2013 to October 2015. The patients received either mycophenolate mofetil (20-30)mg/(kg·d) or cyclosporine A (3-5)mg/(kg·d) randomly, on the basis of prednisone treatment. Follow-up interview was conducted regularly for at least one year. Efficacy rate, relapse rate, time required for induction of remission, relapse-free period and prednisone dosage were compared between the two groups. Results: (1) Renal histologic examination, which was available for 17 patients, revealed minimal change disease in 8 patients, mesangial proliferative glomerulonephritis (MsPGN) in five, membranous nephropathy in two, and focal segmental glomerulosclerosis (FSGS) in two. (2) Comparison of mycophenolate mofetil versus cyclosporine A in children with FRNS: There were 14 patients with FRNS in mycophenolate mofetil group and 18 patients with FRNS in cyclosporine A group respectively. The relapse rate (episodes/year) in cyclosporine A group was lower than that of mycophenolate mofetil group (1.0 (0.0, 1.0) vs. 1.0 (1.0, 3.0), Z=-2.405, P=0.016). The relapse-free period (months) in cyclosporine A group was longer than that of mycophenolate mofetil group (10.0 (5.7, 12.1) vs. 5.0 (1.0, 11.0), Z=-1.984, P=0.047). No significant difference in dosage of prednisone was found between cyclosporine A and mycophenolate mofetil groups when followed up for 1 year. (3) Comparison of mycophenolate mofetil versus cyclosporine A in children with SRNS: The efficacy rate was 6/14 in mycophenolate mofetil group and 13/16 in cyclosporine A group. The complete remission rate was 4/14 in mycophenolate mofetil group and 12/16 in cyclosporine A group (P<0.05). The time (months) required for induction of remission in cyclosporine A group was significantly shorter than that of mycophenolate mofetil group (1.0 (1.0, 2.0) vs. 3.0 (2.5, 4.0), Z=-2.529, P=0.011). No significant differences were found between the two groups with respect to relapse-free period and relapse rate. (4) Except that one patient developed hypertensive encephalopathy in cyclosporine A group, no other serious adverse events were recorded. There were no significant differences between two groups with respect to adverse events. Conclusion: Our results indicated that both mycophenolate mofetil and cyclosporine A were effective in the treatment of children with refractory nephrotic syndrome. Cyclosporine A was superior to mycophenolate mofetil in preventing relapses in patients with FRNS and inducing complete remission in patients with SRNS. Although most patients were able to tolerate mycophenolate mofetil and cyclosporine A, but the toxicity and safety of cyclosporine A should be monitored closely.目的: 比较霉酚酸酯和环孢素A治疗儿童原发性难治性肾病综合征的疗效和安全性。 方法: 采用前瞻性的随机对照临床研究,将2013年10月至2015年10月在首都儿科研究所附属儿童医院肾脏内科住院并诊断儿童原发性肾病综合征的62例患儿(其中男44例,女18例,年龄2.1~17.0岁,包括频复发32例,激素耐药30例),用数字表法随机分为霉酚酸酯组或环孢素A组,分别予以霉酚酸酯20~30mg/(kg·d)或环孢素A 3~5 mg/(kg·d)起始剂量联合泼尼松治疗,定期随访1年。采用秩和检验或Fisher检验,比较两组的治疗有效率、复发频率、诱导缓解时间、维持缓解时间,以及糖皮质激素用量等指标。 结果: (1)62例中17例行肾活检,微小病变8例,系膜增生性肾小球肾炎5例,膜性肾病2例,局灶节段性肾小球硬化2例。(2)对频复发患儿疗效比较:频复发患儿霉酚酸酯组14例,环孢素A组18例。治疗后环孢素A组的复发频率(次/年)低于霉酚酸酯组[1.0(0.0,1.0)比1.0(1.0,3.0),Z=-2.405,P=0.016],维持缓解时间(月)长于霉酚酸酯组[10.0(5.7,12.1)比5.0(1.0,11.0),Z=-1.984,P=0.047]。随访1年时,环孢素A组与霉酚酸酯组糖皮质激素用量差异无统计学意义。(3)对激素耐药患儿疗效比较:总有效率:霉酚酸酯组6/14,环孢素A组13/16;完全缓解率:霉酚酸酯组4/14,环孢素A12/16(P<0.05)。环孢素A组诱导缓解所需时间(月)短于霉酚酸酯组[1.0(1.0,2.0)比3.0(2.5,4.0),Z=-2.529,P=0.011]。两组在维持缓解时间、降低复发频率上差异无统计学意义。(4)除环孢素A组1例患儿发生高血压脑病外,未观测到其他严重不良反应,两组患儿不良反应发生率比较差异无统计学意义。 结论: 霉酚酸酯和环孢素A治疗儿童原发性难治性肾病综合征均有较好疗效;在降低频复发患儿的复发频率以及促进激素耐药患儿完全缓解方面,环孢素A的疗效优于霉酚酸酯。多数患儿可耐受霉酚酸酯或环孢素A的治疗,但应密切监测环孢素A的药物毒性。.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Shawn完成签到,获得积分10
刚刚
小蘑菇应助哈哈哈采纳,获得10
刚刚
1秒前
2秒前
李爱国应助恋雅颖月采纳,获得10
2秒前
3秒前
留白发布了新的文献求助10
3秒前
fdkufghkd完成签到,获得积分10
6秒前
7秒前
7秒前
懵懂的幻桃完成签到 ,获得积分10
7秒前
flyfish完成签到,获得积分10
8秒前
8秒前
上官若男应助斯文莺采纳,获得30
9秒前
10秒前
10秒前
11秒前
Yun发布了新的文献求助10
11秒前
11秒前
11秒前
kyra发布了新的文献求助10
12秒前
xiaoze发布了新的文献求助10
12秒前
13秒前
13秒前
小蘑菇应助Yana1311采纳,获得10
14秒前
14秒前
傻傻的小刺猬完成签到,获得积分10
14秒前
14秒前
14秒前
ColdSunWu发布了新的文献求助10
15秒前
小坤同学发布了新的文献求助10
15秒前
132发布了新的文献求助30
16秒前
轻松小张完成签到,获得积分10
16秒前
量子星尘发布了新的文献求助10
16秒前
shilong.yang发布了新的文献求助10
17秒前
YamDaamCaa应助kk采纳,获得30
17秒前
超帅的不尤完成签到,获得积分20
17秒前
桐桐应助mariawang采纳,获得10
18秒前
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021